Copy
CTT Pharmaceuticals Secures $3 Million Equity Line
Tampa, Florida — September 10, 2025 — Leads & Copy — CTT Pharmaceuticals Holdings, Inc. (OTCQB:CTTH) has signed a contract for a $3 million equity line of credit. The funds will be used for manufacturing CTT's patented technology. CTT will immediately move forward with an S-1 filing to become an SEC reporting company and will notify shareholders in greater detail once the equity line becomes available.
CTT Pharma has not been notified of an approval or denial from the NIH for clinical trials with Johns Hopkins University but will notify shareholders once this information becomes available.
CTT’s submission to the National Science Foundation (NSF) Grant Program remains under review, with a funding decision anticipated towards the end of the fourth quarter.
The Small Business Association (SBA) is expected to notify CTT regarding potential approval for a loan, which, if awarded, will be directed towards manufacturing.
Our scientists are finalizing a manuscript for submission to a peer-reviewed journal and look forward to sharing the publication once peer review is complete and the manuscript has been accepted.
The PCAOB audit firm that CTT hired successfully completed an audit for 2024, bringing CTT to 3 years of PCAOB audits completed.
CTT Pharma – 813-606-0060